Login to Your Account



Vertex Reports Positive Results From Second Pivotal HIV Study

By Randall Osborne


Monday, May 20, 2002
Vertex Pharmaceuticals Inc. said collaborator GlaxoSmithKline plc is likely to file for approval of the HIV protease inhibitor GW433908 - which last month entered its third pivotal Phase III trial - by the end of the year in the U.S. and Europe. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription